Letter of Support from Takeda Pharmaceuticals

February 13, 2019

The Hemophilia Alliance Board of Directors
1758 Allentown Road #183
Lansdale, PA 19446

Dear Board of Directors,

Takeda Pharmaceuticals U.S.A. Inc. is committed to ensuring that patients obtain the most appropriate treatment based on their individual healthcare needs. This includes access to medically appropriate treatment, comprehensive hemophilia treatment centers, as well as choice of experienced pharmacy providers, including pharmacy programs administered by hemophilia treatment centers as part of the 340B drug discount program.

Hemophilia treatment centers are federally recognized facilities that provide a comprehensive model of care for people with bleeding disorders. Patients receive coordinated care within one facility which is typically comprised of a multi-disciplinary team of experts in hemophilia including hematologists, pediatricians, nurses, social workers and physical therapists. Research at the Centers for Disease Control and Prevention documented a decrease in mortality and bleed-related hospitalization in men who visited a hemophilia treatment center.1

Hemophilia treatment centers are included in a specific category of HRSA grantees that participate in the 340B drug discount program. The 340B program has served as a source of funding for comprehensive hemophilia care and has helped hemophilia treatment centers provide access to high quality hemophilia care to all patients, both insured and uninsured.

Takeda continues to believe that each patient should have access to the medically appropriate treatment and provider to meet their individual needs. Pharmacy programs administered by 340B eligible hemophilia treatment centers are an option that should be available to all patients.


Andrew Kaplan
Vice President, U.S. Public Affairs
Takeda Pharmaceuticals U.S.A., Inc.

1 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1449458/

Takeda Pharmaceuticals’ letter of support: Click here.

Comments are closed.